People living with Sjögren’s disease (SjD) around the world need additional treatment options that can help address the serious health consequences of this complex and heterogeneous disease driven by autoantibody production that causes chronic dryness of the mucosal membranes (eyes, mouth, vagina, etc.) and inflammation that may affect multiple organ systems.
SjD is one of the most prevalent autoantibody-driven diseases, estimated to impact as many as four million people worldwide.Patients with systemic SjD manifestations and symptoms that interfere with daily activities and quality of life continue to experience high unmet need for approved therapies with a proven safety profile that effectively addresses the underlying causes of SjD.
J&J’s approach to Sjögren’s disease (SjD)
Building on our legacy of leadership in immunology innovation, we are currently evaluating an immunoselective treatment, designed to lower IgG potentially without impact on other immune functions. This investigational therapy is being studied across multiple auto- and alloantibody-driven diseases, including SjD.
